FOLH1 and posterior cortical atrophy: A diagnostic PET radiopharmaceutical, 18F-flotufolastat (18F-rhPSMA-7.3), developed using this platform was recently approved by the Food and Drug Administration for PSMA PET in men with PCa (12–14).